EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Thiazolyl–Pyrazoline Derivatives as Potential EGFR Inhibitors

Mayuri A Patil iD, Sachin S Bhusari, Pravin S Wakte

Chemical Biology & Drug Design · 2026-06 · 107 (6)

DOI: 10.1111/cbdd.70345 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 23.06.2026. Verfasst von Mayuri A Patil und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Technology, Dr. Babasaheb Ambedkar Marathwada University, Chhatrapati Sambhajinagar, Maharashtra, India. Hauptthemen laut MEDLINE: ErbB Receptors, Pyrazoles, Thiazoles, Drug Design. Die Arbeit nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A novel series of thiazolyl–pyrazoline derivatives (MAP‐1 to MAP‐20) was designed and synthesized as potential epidermal growth factor receptor (EGFR) inhibitors. The structures of all compounds were confirmed by 1 H NMR, 13 C NMR, and HRMS analyses. The synthesized derivatives were evaluated for in vitro anticancer activity using the MTT assay against MCF‐7 (breast), A549 (lung), HeLa (cervical), and non‐tumorigenic MCF‐10A cell lines. Among the tested compounds, MAP‐13, MAP‐15, and MAP‐19 exhibited potent cytotoxic activity against MCF‐7 (IC 50 = 1.09 ± 0.8, 2.33 ± 0.84, and 2.11 ± 0.26 μM, respectively), A549 (IC 50 = 2.06 ± 0.16, 2.81 ± 0.16, and 2.76 ± 0.42 μM, respectively), and HeLa cells (IC 50 = 1.18 ± 0.9, 2.27 ± 0.18, and 2.15 ± 0.36 μM, respectively), with improved selectivity over normal MCF‐10A cells. Molecular docking studies against EGFR (PDB ID: 4I23) revealed strong binding affinities, with docking scores of −8.67, −9.31, and −9.00 kcal/mol for MAP‐13, MAP‐15, and MAP‐19, respectively. Key interactions within the ATP‐binding pocket suggested stable ligand–receptor complex formation. In silico ADMET profiling confirmed acceptable drug‐likeness and pharmacokinetic properties for the lead compounds. These findings indicate that thiazolyl–pyrazoline hybrids represent promising scaffolds for the development of selective EGFR‐targeted anticancer agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsPyrazolesThiazolesDrug DesignAntineoplastic AgentsProtein Kinase InhibitorsHumansMolecular Docking SimulationCell Line, TumorBinding SitesMCF-7 CellsHeLa Cells

Stichwörter der Autor:innen

EGFR inhibitorsanticancerkinase inhibitionmolecular dockingthiazolyl–pyrazoline

Substanzen

ErbB ReceptorsPyrazolesThiazolesAntineoplastic AgentsProtein Kinase InhibitorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Chemical Technology, Dr. Babasaheb Ambedkar Marathwada University, Chhatrapati Sambhajinagar, Maharashtra, India.

ORCID-Profile: Mayuri A Patil

Zitieren

APA

Patil, M. A., Bhusari, S. S., & Wakte, P. S. (2026). Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Thiazolyl–Pyrazoline Derivatives as Potential EGFR Inhibitors. Chemical Biology & Drug Design, 107(6). https://doi.org/10.1111/cbdd.70345

Vancouver

Patil MA, Bhusari SS, Wakte PS. Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Thiazolyl–Pyrazoline Derivatives as Potential EGFR Inhibitors. Chemical Biology & Drug Design. 2026;107(6). doi:10.1111/cbdd.70345

BibTeX
@article{Patil2026,
  author = {Patil, Mayuri A and Bhusari, Sachin S and Wakte, Pravin S},
  title = {Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Thiazolyl–Pyrazoline Derivatives as Potential EGFR Inhibitors},
  journal = {Chemical Biology & Drug Design},
  year = {2026},
  volume = {107},
  number = {6},
  doi = {10.1111/cbdd.70345}
}
Kostenlos starten →